

## Consolidated Statements of Cash Flows

	Years Ended December 31,		
	2001	2000	1999
	<i>(in thousands of dollars)</i>		
<b>Cash flows from operating activities:</b>			
Net loss	\$ (17,464)	\$ (18,788)	\$(11,296)
Adjustments to reconcile net loss to net cash provided by (used in) operating activities:			
Depreciation and amortization	647	343	412
Acquired in-process research and development	—	4,969	—
Non-cash compensation related to stock options	732	1,036	217
Issuance of common stock to acquire minority interest of Theracell, Inc.	—	—	136
Other	—	—	13
Changes in operating assets and liabilities:			
Prepaid expenses, receivables and other current assets	(955)	20	(575)
Accounts payable	(410)	(931)	438
Accrued clinical trials and other liabilities	1,711	188	(200)
Deferred contract revenue	2,000	—	—
Net cash used in operating activities	(13,739)	(13,163)	(10,855)
<b>Cash flows from investing activities:</b>			
Purchases of property and equipment, net	(254)	(374)	(185)
Investment in other companies	(600)	—	—
Purchases of marketable securities	(72,733)	(167,355)	—
Proceeds from maturities of marketable securities	55,750	51,550	—
Proceeds from sales of marketable securities	16,127	19,273	—
Net cash used in investing activities	(1,710)	(96,906)	(185)
<b>Cash flows from financing activities:</b>			
Issuance of common stock, net	921	83,915	45,839
Net cash provided by financing activities	921	83,915	45,839
<b>Net increase (decrease) in cash and cash equivalents</b>	<b>(14,528)</b>	<b>(26,154)</b>	<b>34,799</b>
Cash and cash equivalents at beginning of year	20,300	46,454	11,655
<b>Cash and cash equivalents at end of year</b>	<b>5,772</b>	<b>20,300</b>	<b>46,454</b>
Marketable securities at end of year	99,279	97,223	—
<b>Cash, cash equivalents and marketable securities at end of year</b>	<b>\$105,051</b>	<b>\$ 117,523</b>	<b>\$ 46,454</b>
<i>Schedule of non-cash transaction:</i>			
Issuance of common stock to acquire technology, net	\$ —	\$ 3,522	\$ —
<i>See accompanying notes.</i>			